PNC Financial Services Group Inc. Sells 29,820 Shares of Alkermes Plc (NASDAQ:ALKS)
PNC Financial Services Group Inc. Sells 29,820 Shares of Alkermes Plc (NASDAQ:ALKS)
PNC Financial Services Group Inc. cut its holdings in shares of Alkermes plc (NASDAQ:ALKS – Get Rating) by 22.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 100,771 shares of the company's stock after selling 29,820 shares during the quarter. PNC Financial Services Group Inc.'s holdings in Alkermes were worth $2,652,000 as of its most recent SEC filing.
根据Alkermes公司最近向美国证券交易委员会披露的信息,PNC金融服务集团在第一季度减持了22.8%的Alkermes公司股票。该公司在本季度出售了29,820股后,持有100,771股该公司股票。截至最近提交给美国证券交易委员会的文件,PNC金融持有的艾尔建股份价值2,652,000美元。
Other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC bought a new position in shares of Alkermes during the first quarter worth approximately $874,000. Qube Research & Technologies Ltd boosted its position in shares of Alkermes by 242.9% during the 1st quarter. Qube Research & Technologies Ltd now owns 35,680 shares of the company's stock worth $939,000 after acquiring an additional 25,276 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Alkermes by 21.0% during the 4th quarter. California Public Employees Retirement System now owns 304,982 shares of the company's stock worth $7,094,000 after acquiring an additional 52,967 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Alkermes by 1.4% during the 4th quarter. Renaissance Technologies LLC now owns 4,810,945 shares of the company's stock worth $111,903,000 after acquiring an additional 66,463 shares in the last quarter. Finally, Sarissa Capital Management LP boosted its position in shares of Alkermes by 6.3% during the 4th quarter. Sarissa Capital Management LP now owns 14,040,000 shares of the company's stock worth $326,570,000 after acquiring an additional 827,000 shares in the last quarter. 94.77% of the stock is owned by institutional investors.
其他对冲基金最近也对他们在该公司的头寸进行了调整。Jennison Associates LLC在第一季度购买了价值约87.4万美元的Alkermes股票的新头寸。Qube Research&Technologies Ltd在第一季度将其在Alkermes股票的头寸增加了242.9%。Qube Research&Technologies Ltd在上个季度增持了25,276股后,现在拥有35,680股该公司股票,价值939,000美元。加州公共雇员退休系统在第四季度将其在Alkermes股票的头寸增加了21.0%。加州公共雇员退休系统现在拥有304,982股公司股票,价值7,094,000美元,上个季度又购买了52,967股。复兴科技有限责任公司在第四季度将其在Alkermes股票的头寸增加了1.4%。复兴科技有限责任公司在上个季度增持了66,463股后,现在拥有4,810,945股该公司股票,价值111,90.3万美元。最后,Sarissa Capital Management LP在第四季度将其在Alkermes股票的头寸增加了6.3%。Sarissa Capital Management LP在上个季度增持了827,000股后,现在拥有14,040,000股该公司股票,价值326,57万美元。94.77%的股票由机构投资者持有。
Insider Buying and Selling
内幕买卖
In related news, SVP Christian Todd Nichols sold 7,474 shares of Alkermes stock in a transaction on Tuesday, June 21st. The shares were sold at an average price of $28.26, for a total transaction of $211,215.24. Following the completion of the transaction, the senior vice president now owns 21,035 shares of the company's stock, valued at $594,449.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.76% of the stock is owned by insiders.
在相关新闻中,高级副总裁克里斯蒂安·托德·尼科尔斯在6月21日(星期二)的一笔交易中出售了7,474股Alkermes股票。这些股票以28.26美元的平均价格出售,总成交金额为211,215.24美元。交易完成后,高级副总裁现在拥有该公司21,035股股票,价值594,449.10美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可通过以下链接获得。4.76%的股份由内部人士持有。
Analyst Ratings Changes
分析师评级发生变化
Alkermes Price Performance
Alkermes性价比
Shares of NASDAQ:ALKS opened at $24.51 on Monday. The firm has a market cap of $4.03 billion, a PE ratio of -43.00 and a beta of 0.60. The firm's fifty day moving average is $27.72 and its 200-day moving average is $27.47. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.03 and a current ratio of 2.39. Alkermes plc has a 52 week low of $21.24 and a 52 week high of $33.00.
纳斯达克:ALKS周一开盘报24.51美元。该公司市值为40.3亿美元,市盈率为-43.00,贝塔系数为0.60。该公司的50日移动均线切入位为27.72美元,200日移动均线切入位为27.47美元。该公司的负债权益比率为0.27,速动比率为2.03,流动比率为2.39。Alkermes plc股价52周低点为21.24美元,52周高点为33.00美元。
Alkermes (NASDAQ:ALKS – Get Rating) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.01 by $0.05. The company had revenue of $276.22 million for the quarter, compared to analyst estimates of $269.01 million. Alkermes had a negative net margin of 8.02% and a positive return on equity of 0.79%. Alkermes's revenue was down 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Sell-side analysts predict that Alkermes plc will post -0.34 earnings per share for the current year.
艾尔建(纳斯达克代码:ALKS-GET Rating)最近一次发布季度收益报告是在7月27日星期三。该公司公布本季度每股收益为0.06美元,比分析师普遍预期的0.01美元高出0.05美元。该公司本季度营收为2.7622亿美元,而分析师预期为2.6901亿美元。Alkermes的净利润率为负8.02%,股本回报率为正0.79%。与去年同期相比,Alkermes的收入下降了9.1%。去年同期,该业务每股收益为0.13美元。卖方分析师预计,alkermes plc本年度每股收益将为0.34欧元。
About Alkermes
关于阿尔克姆斯
(Get Rating)
(获取评级)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases.
Alkermes plc是一家生物制药公司,研究、开发和商业化药物产品,以满足美国、爱尔兰和国际上不同治疗领域患者未得到满足的医疗需求。其销售的产品包括用于治疗精神分裂症的肌肉注射混悬剂Aristada;用于治疗酒精和防止阿片类药物依赖的VIVITROL;用于治疗精神分裂症和双相I型障碍的Risperdal Consta;用于治疗精神分裂症和分裂情感障碍的INVEGA SUSTENNA;用于治疗精神分裂症和分裂情感障碍的XEPLION、INVEGA TRINZA和TREVICTA;以及用于治疗成人复发形式的多发性硬化症的VUMERITY,包括临床孤立综合征、复发缓解和活跃的继发性进行性疾病。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Alkermes (ALKS)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
- 免费获取StockNews.com关于Alkermes的研究报告(ALKS)
- 随着管理层重组,股市能否迅速反弹?
- MarketBeat:回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
- 露露柠檬将飙升至9月
- 耐克股票会被超卖,但仍被高估吗?
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Get Rating).
想看看还有哪些对冲基金持有ALKS吗?访问HoldingsChannel.com获取Alkermes plc(纳斯达克代码:ALKS-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
接受Alkermes Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Alkermes和相关公司的最新新闻和分析师评级的每日简要摘要。